CDK4/6 抑制剂在早期乳腺癌中的作用。
The role of CDK4/6 inhibitors in early breast cancer.
机构信息
Institut Català d'Oncologia IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.
出版信息
Breast. 2021 Aug;58:160-169. doi: 10.1016/j.breast.2021.05.008. Epub 2021 May 25.
Abstract
The use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has proven to be a successful strategy in the treatment of advanced hormone receptor-positive (HR) and human epidermal growth factor receptor 2-negative (HER2) breast cancer (BC), leading to a strong interest in their possible role in the treatment of early luminal BC. In this review we collect the most relevant and recent information on the use of CDK4/6i for the treatment of early BC in the neoadjuvant and adjuvant settings. Specifically, we evaluate the results of the large phase 3 adjuvant trials recently released, which have yielded apparently divergent results. We also examine the relevance of biomarkers as response predictive factors for CDI4/6i, the combination between radiotherapy and CDK4/6i, and provide a critical discussion on the evidence that we have so far and future directions of the role of these drugs in the treatment of early BC.
摘要
CDK4/6 抑制剂（CDK4/6i）在治疗晚期激素受体阳性（HR）和人表皮生长因子受体 2 阴性（HER2）乳腺癌（BC）方面已被证明是一种成功的策略，这引起了人们对其在早期 luminal BC 治疗中可能发挥作用的强烈兴趣。在这篇综述中，我们收集了关于 CDK4/6i 在新辅助和辅助治疗早期 BC 中的应用的最相关和最新信息。具体来说，我们评估了最近公布的大型 III 期辅助试验的结果，这些试验得出了明显不同的结果。我们还研究了生物标志物作为 CDI4/6i 反应预测因素的相关性，以及放疗和 CDK4/6i 的联合应用，并对我们迄今所拥有的证据以及这些药物在早期 BC 治疗中的作用的未来方向进行了批判性讨论。
相似文献
1
The role of CDK4/6 inhibitors in early breast cancer.CDK4/6 抑制剂在早期乳腺癌中的作用。
Breast. 2021 Aug;58:160-169. doi: 10.1016/j.breast.2021.05.008. Epub 2021 May 25.
2
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment.CDK4/CDK6 抑制剂在激素受体阳性乳腺癌治疗中的敏感性和耐药机制。
Drug Resist Updat. 2024 Sep;76:101103. doi: 10.1016/j.drup.2024.101103. Epub 2024 Jun 25.
3
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.乳腺癌中 CDK4/6 抑制剂策略及联合治疗的最新进展。
Cells. 2019 Apr 6;8(4):321. doi: 10.3390/cells8040321.
4
CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.用于治疗晚期激素受体阳性乳腺癌及其他疾病的CDK4/6抑制剂：2016年更新
Expert Opin Pharmacother. 2016 Aug;17(12):1657-67. doi: 10.1080/14656566.2016.1201072. Epub 2016 Jun 27.
5
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.细胞周期蛋白依赖性激酶 4/6 抑制剂在激素受体阳性早期乳腺癌中的应用：初步结果和正在进行的研究。
Breast Cancer. 2018 Sep;25(5):506-516. doi: 10.1007/s12282-018-0864-6. Epub 2018 Apr 26.
6
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.在德国药物可获得的头 2 年中，来自 PRAEGNANT 研究网络的数据：与常规临床应用中激素受体阳性、HER2 阴性乳腺癌患者的抗激素单药治疗相比，CDK4/6 抑制剂治疗的初步经验。
Breast. 2020 Dec;54:88-95. doi: 10.1016/j.breast.2020.08.011. Epub 2020 Aug 29.
7
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.CDK4/6 抑制剂拓展乳腺癌治疗选择：哌柏西利、瑞博西利和阿贝西利。
BioDrugs. 2019 Apr;33(2):125-135. doi: 10.1007/s40259-019-00337-6.
8
Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).日本激素受体阳性 HER2 阴性晚期和转移性乳腺癌中 CDK4/6 抑制剂耐药的高危患者检测（KBCSG-TR-1316）。
Breast Cancer. 2023 Nov;30(6):943-951. doi: 10.1007/s12282-023-01485-y. Epub 2023 Jul 24.
9
Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.激素受体阳性转移性乳腺癌中 CDK 抑制剂在首次疾病进展后继续使用的真实世界结局。
Clin Breast Cancer. 2021 Jun;21(3):205-209. doi: 10.1016/j.clbc.2020.09.010. Epub 2020 Oct 2.
10
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.细胞周期蛋白依赖性激酶 4/6 抑制剂在乳腺癌中的应用：帕博西尼、瑞博西尼和阿贝西利。
Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24.
引用本文的文献
1
Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy.试验定义的高危激素受体阳性/人表皮生长因子受体II阴性早期乳腺癌的生存结果：辅助化疗的影响
Discov Oncol. 2025 May 16;16(1):783. doi: 10.1007/s12672-025-02601-4.
2
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment.细胞周期蛋白依赖性激酶4和6抑制剂在乳腺癌治疗中的应用
Oncogene. 2025 May;44(17):1135-1152. doi: 10.1038/s41388-025-03378-0. Epub 2025 Apr 8.
3
Breast Cancer Patient's Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II-III Disease.II-III期疾病患者新辅助化疗及手术后5年和10年的乳腺癌患者预后
Cancers (Basel). 2024 Jun 30;16(13):2421. doi: 10.3390/cancers16132421.
4
Assessing Knowledge, Competence, and Performance Following Web-Based Education on Early Breast Cancer Management: Health Care Professional Questionnaire Study and Anonymized Patient Records Analysis.基于网络的早期乳腺癌管理教育后的知识、能力和表现评估：医疗保健专业人员问卷调查研究与匿名患者记录分析
JMIR Form Res. 2024 Mar 21;8:e50931. doi: 10.2196/50931.
5
Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors.术后放疗与细胞周期蛋白依赖性激酶（CDK）抑制剂的联合应用。
Curr Oncol Rep. 2023 Oct;25(10):1153-1159. doi: 10.1007/s11912-023-01444-y. Epub 2023 Aug 25.
6
Therapeutic resistance to anti-oestrogen therapy in breast cancer.乳腺癌对抗雌激素治疗的耐药性。
Nat Rev Cancer. 2023 Oct;23(10):673-685. doi: 10.1038/s41568-023-00604-3. Epub 2023 Jul 27.
7
Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review.在乳腺癌治疗中环细胞依赖性激酶 4/6 抑制剂的作用：一项有针对性的文献综述。
Target Oncol. 2023 May;18(3):327-358. doi: 10.1007/s11523-023-00957-7. Epub 2023 Apr 19.
8
The Combination of CDK 4/6 Inhibitors plus Endocrine Treatment versus Endocrine Treatment Alone in Hormone-receptor (HR)-Positive breast Cancer: a Systematic Review and Meta-analysis.CDK4/6 抑制剂联合内分泌治疗与单独内分泌治疗用于激素受体（HR）阳性乳腺癌：系统评价和荟萃分析。
Med Arch. 2022 Oct;76(5):333-342. doi: 10.5455/medarh.2022.76.333-342.
9
Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion.无基因突变的同步可手术胰腺癌和乳腺癌：文献综述与讨论
Front Surg. 2022 Jun 24;9:858349. doi: 10.3389/fsurg.2022.858349. eCollection 2022.
10
Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review.CDK4/6抑制剂联合内分泌治疗晚期激素受体阳性（HR+）和人表皮生长因子受体2阴性（HER2-）乳腺癌的药物经济学评价：一项系统综述
Ann Transl Med. 2022 Feb;10(4):233. doi: 10.21037/atm-21-5110.
本文引用的文献
1
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.MONALEESA 三期临床试验的 ctDNA pooled 分析。
Ann Oncol. 2023 Nov;34(11):1003-1014. doi: 10.1016/j.annonc.2023.08.011. Epub 2023 Sep 5.
2
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.循环肿瘤 DNA 中 PIK3CA 和 ESR1 突变的临床意义：来自 abemaciclib 联合氟维司群的 MONARCH 2 研究的分析。
Clin Cancer Res. 2022 Apr 14;28(8):1500-1506. doi: 10.1158/1078-0432.CCR-21-3276.
3
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial.帕博西尼用于残留高危侵袭性 HR 阳性和 HER2 阴性早期乳腺癌 - Penelope-B 试验。
J Clin Oncol. 2021 May 10;39(14):1518-1530. doi: 10.1200/JCO.20.03639. Epub 2021 Apr 1.
4
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.帕博西尼联合辅助内分泌治疗早期乳腺癌（PALLAS）：多中心、开放标签、随机、III 期研究的中期分析。
Lancet Oncol. 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15.
5
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.帕博西尼、瑞博西尼和阿贝西利联合抑制 CDK4/6 在乳腺癌中的应用：相似与不同。
Drugs. 2021 Feb;81(3):317-331. doi: 10.1007/s40265-020-01461-2. Epub 2020 Dec 28.
6
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.绝经后激素敏感型早期乳腺癌（POETIC）患者围手术期内分泌治疗后 Ki67 的长期预后价值：一项开放标签、多中心、平行组、随机、III 期临床试验。
Lancet Oncol. 2020 Nov;21(11):1443-1454. doi: 10.1016/S1470-2045(20)30458-7.
7
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).阿贝西利联合内分泌治疗用于 HR+、HER2-、淋巴结阳性、高危、早期乳腺癌的辅助治疗（monarchE）。
J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
8
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization.CDK4/6 抑制剂：一种肿瘤放射增敏的新策略。
J Exp Clin Cancer Res. 2020 Sep 15;39(1):188. doi: 10.1186/s13046-020-01693-w.
9
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.激素受体阳性转移性乳腺癌患者中细胞周期蛋白依赖性激酶 4/6 抑制剂的内在和获得性耐药的基因组特征
Cancer Discov. 2020 Aug;10(8):1174-1193. doi: 10.1158/2159-8290.CD-19-1390. Epub 2020 May 13.
10
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.TREnd 试验中接受帕博西尼治疗的腔面转移性乳腺癌患者中，血浆胸苷激酶活性作为生物标志物。
Clin Cancer Res. 2020 May 1;26(9):2131-2139. doi: 10.1158/1078-0432.CCR-19-3271. Epub 2020 Jan 14.
Zotero 插件